May 21, 2009
OSN SuperSite
PETACH TIKVA, Israel — Can-Fite BioPharma's phase 2 clinical trial of an investigational oral treatment for dry eye syndrome has met the primary efficacy endpoint of relieving signs and symptoms of related ocular surface inflammation, the company announced in a press release.
The drug, called CF101, targets A3 adenosine receptors on the surface of pathologic cells.
In the masked study, 80 patients with moderate to severe dry eye were randomly assigned to receive either 1 mg of oral CF101 or placebo monotherapy for 12 weeks. According to fluorescein staining measurements, patients who received CF101 experienced a statistically significant improvement in superficial punctate keratitis. In addition, the compound was safe and well-tolerated.
The investigators also found that patients who received oral CF101 demonstrated a decrease in IOP, suggesting that adenosine A3 agonists may show benefit for treating glaucoma, the release said.
No comments:
Post a Comment